initi outperform pt
novaseq still aid instrument growth clinic expand
upgrad share earli last year like boldest call
year cover stock hard get drawn
compel new product cycl inde turn
clock expect broaden adopt
launch chip crucial get high volum user onto
new system support box growth furthermor see plethora
new opportun clinic front oncolog clearli star
promis liquid biopsi ever present term long term tam
expans also look array demand sustain slightli elev
level consum market fuel strong servic growth base
nih budget increas help tradit research
innov engin like remain robust sustain scarciti valu
anoth potenti upsid surpris could come form notabl new
product introduct focu next week
littl chatter new box possibl applic may point
valuat limit would note increment margin
gain momentum upsid bia could
see ep estim move higher speak valuat believ
continu strong instrument momentum sustain elev multipl
broadli allow superior growth profil remain roll
remain one uniqu growth stori across
entir market leverag futur cancer person
medicin via domin presenc given dynam
see risk reward favor thu initi share o/p rate
thing watch pace novaseq placement overal
util new product introduct
debat novaseq adopt curv
long array growth remain elev next big
opportun clinic genom
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average
price-to-earnings basi translat vs average
downsid risk potenti disrupt us fund given
challeng feder budget us could delay uptak new capit
purchas difficulti relat scale comput power storag
rate data gener could limit pace clinic adopt
time-fram translat scientif discoveri tangibl clinic
applic take longer fear given unforeseen complex
emerg technolog prove scalabl contempl
 slowdown yield materi shift long term share array return
challeng growth given increas competit well
draw back relat tool consum style shift
growth valu compress multipl broadli lead notabl step-
absolut valuat metric
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi outperform pt
last page report import disclosur regard stock report
tabl content
compani overview world leader genet analysi
debat novaseq adopt curv
debat long array growth remain elev
debat next big opportun clinic genom
point differenti vs st
iv valuat risk
 conclus initi o/p new product momentum
san diego ca world leader genet analysi
domin provid microarray tool
sequenc technolog life scienc clinic
market w/ notabl presenc array
thesi early-to-mid cycl uptak novaseq
inflect clinic demand continu new product
momentum improv omx cadenc must
rate valuat pt outperform pt
ebitda vs average
price-to-earnings vs average
risk uptak clinic take longer
sequenc consum key product segment
new manag built histori innov
join symantec
join cardin health
mostafa ronaghi svp
co-found acceler
join variou role genentech
visionari overal genom gangster
debat novaseq adopt curv
surpass initi expect placement
surprisingli upsid come commercial/clin
still earli w/ cust like speed adopt
believ support elev multipl
yet dent initi address high
earli demand novaseq
order come custom new
sequenc new high throughput sequenc
hiseq custom upgrad
major custom wait chip
earli launch acceler replac
thu drive next leg adopt
though earli day nova launch initi success like sustain elev multipl
debat long array growth remain elev
declar dead array roar back life
servic drive much improv growth
array total rev
servic array rev
array servic demand driven dtc opportun
enjoy last dtc convert
ilmn array backlog grown highest level sinc
array appear back near term servic
growth driven larg rabid demand dtc genom
howev difficult tell dtc genom
convert wide acknowledg happen
cost continu drop
tend believ array rel safe
transit next year two
lt imagin array nich product use
confirm result front prep studi etc
larg commodit growth
reflect dynam
lazaru genom provid nice nt boost core like long-liv
debat next big opportun clinic genom
open clinic market key expand tam
liquid biopsi test materi unlock clinic
liquid biopsi technolog wide consid
key unlocking/expand clinic genom market
cancer diagnos use liquid biopsi
hand test develop approv
holi grail pardon pun cancer test
spun grail develop test major
challeng exist expect updat trial progress
aim develop annual screen test
given peopl risk develop cancer
year key valid thesi
nascent market liq biopsi oppti massiv
new applic tech present notabl expans
liquid biopsi market mm today
major
address
liquid biopsi like compel mt oppti
singl cell provid understand differenti
requir lot sequenc small project
 lower sequenc cost expand potenti
cdx i/o i/o drug develop
receiv approv china nextseq nipt
launch veriseq nipt europ
consum genom increas number compani
w/ high-risk screen repres biggest oppti
model summari point differenti vs street
swing factor pace instrument growth degre novaseq util next leg growth
point differenti
pace adopt
begin normal
hit full run-rat
ep notabl st
growth cash unlock
multipl normal
key product
revenu momentum continu given improv omx drive ep beat
million except per share data fy end decemb sequenc organ gp less op less ep share inc net inc price-to-earnings prem disc januari
valuat elev correspond w/ mid-cycl growth path
pt in-lin w/ long term averag price-to-earnings correspond p/e/g consist w/ growth asset
risk point favor risk reward profil delay clinic uptak vs sheer opportun
potenti disrupt us fund given challeng feder budget us could delay uptak new capit purchas
difficulti relat scale comput power storag rate data gener could limit pace clinic adopt
time-frame translat scientif discoveri tangibl clinic applic take longer fear given unforeseen complex
emerg technolog prove scalabl contempl slowdown yield materi shift long term share
array return challeng growth given increas competit well draw back relat tool consum
style shift growth valu compress multipl broadli lead notabl step-down absolut valuat metric
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris tax valu grail total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi outperform pt upsid
strong novaseq growth new product momentum clinic opportun improv omx pull back
upgrad share earli last year like boldest call year cover
stock hard get drawn compel new product cycl inde
turn clock expect broaden adopt launch
chip crucial get high volum user onto new system support box growth
furthermor see plethora new opportun clinic front oncolog clearli
star promis liquid biopsi ever present term long term expans
also look array demand sustain slightli elev level consum market fuel
strong servic growth base nih budget increas help tradit research
anoth potenti upsid surpris could come form notabl new product introduct
focu next week littl chatter new box possibl applic
may point valuat limit would note increment margin
gain momentum upsid bia could see ep estim move higher
speak valuat believ continu strong instrument momentum sustain
elev multipl broadli allow superior growth profil remain
roll remain one uniqu growth stori across entir market
leverag futur cancer person medicin via domin presenc
given dynam see risk reward favor thu initi share o/p rate
thing watch pace novaseq placement util new product intro
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
